| Human MMP-9 Protein (LTP11008) |
| LTP11008 |
| 100ug |
|
$473 In stock |
| Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. |
| Recombinant Human MMP-9 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. The protein needs to be activated by APMA to have hydrolytic activity. It contains Ala20-Asp707. |
| MMP-9 |
| Human |
| P14780 |
| Ala20-Asp707 |
| The protein has a predicted MW of 79.3 kDa. Due to glycosylation, the protein migrates to 85-100 kDa based on the Tris-Bis PAGE result. |
| Immobilized Human MMP-9, His Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-MMP-9 Antibody, hFc Tag with the EC50 of 17.4ng/ml determined by ELISA. See testing image for detail. |
| C-His-Avi |
| Expi293 |
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| |